New trials, publications, preprints and grants on this target, month by month.
Publication
Soxataltinib, a highly selective CNS-penetrant RET inhibitor demonstrates durable activity in RET fusion-positive non-small cell lung cancer phase 2 study.
5 Nov 2026· Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer· PUBMED
Publication
Clinical features and outcomes of MEN2A with RET codon 634 pathogenic variants.
31 Oct 2026· Journal of the Endocrine Society· PUBMED
Publication
RET fusion-positive non-small cell lung cancer in Sweden: a nationwide registry study.
29 Oct 2026· Acta oncologica (Stockholm, Sweden)· PUBMED
Publication
Adjuvant selpercatinib improved EFS in early-stage RET-positive NSCLC.
15 Oct 2026· Cancer· PUBMED
Publication
Shrimp-derived peptides restore spermatogenesis by activating the GDNF/GFRα1/c-RET pathway in a rat model of NAFLD.
15 Oct 2026· F&S science· PUBMED
Publication
Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study.
14 Oct 2026· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publication
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry.
14 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Drug-specific resistance mechanisms to RET inhibitors in RET fusion-positive NSCLC.
8 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Commentary: Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: a network meta-analysis of RET-targeted therapies.
5 Oct 2026· Frontiers in endocrinology· PUBMED
Trial
A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India
1 Oct 2026· PHASE4 · NOT_YET_RECRUITING· CTGOV
Publication
From Genomic Insight to Clinical Impact: Dramatic Response in RET Fusion-positive Pancreatic Cancer.
1 Oct 2026· Anticancer research· PUBMED
Publication
The impact of RET fusions on radioiodine avidity and prognosis in patients with distant metastatic papillary thyroid cancer.
28 Sept 2026· Endocrine· PUBMED
Publication
EML4::RET, a novel transcript fusion in papillary thyroid cancer.
16 Sept 2026· JCEM case reports· PUBMED
Publication
Tumor-Agnostic and Histology-Tuned Targeted Therapies in Gastrointestinal Cancers: NTRK and RET Fusions and the Evolving Role of Molecular Basket Strategies.
4 Sept 2026· Journal of gastrointestinal cancer· PUBMED
Publication
Retraction: Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity.
3 Sept 2026· PloS one· PUBMED
Trial
A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation
1 Sept 2026· PHASE3 · RECRUITING· CTGOV
Publication
Expert consensus on the reporting and clinical follow up of individuals with incidentally discovered germline RET variants in the UK.
1 Sept 2026· Endocrine-related cancer· PUBMED
Publication
Acquired TPM3::NTRK1 fusion as a novel off-target resistance mechanism to selpercatinib in RET-positive lung adenocarcinoma: a case report.
28 Aug 2026· Frontiers in oncology· PUBMED
Publication
Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.
27 Aug 2026· Investigational new drugs· PUBMED
Publication
RET-driven osteoprotegerin expression links medullary thyroid cancer to osteoblastic bone metastases.
27 Aug 2026· Cell reports. Medicine· PUBMED
Publication
Clinical Outcomes of the Germline RET M918T Pathogenic Variant in Hereditary Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
26 Aug 2026· Medicina (Kaunas, Lithuania)· PUBMED
Publication
Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer.
23 Aug 2026· Bioorganic chemistry· PUBMED
Publication
Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer.
14 Aug 2026· Frontiers in oncology· PUBMED
Publication
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; camizestrant for breast cancer, ivosidenib for biliary tract cancer, subcutaneous isatuximab and talquetamab plus teclistamab for multiple myeloma, isotretinoin for neuroblastoma, selpercatinib for pediatric RET-altered tumors, tafasitamab for lymphoma, and tislelizumab and durvalumab for gastric cancer.
1 Aug 2026· International journal of clinical oncology· PUBMED
Publication
Development of clinical-radiological prediction models to prioritize ALK, ROS1, and RET fusion testing in major driver alteration-negative non-small cell lung cancer.
30 Jul 2026· Journal of thoracic disease· PUBMED
Publication
RET alterations in thyroid cancer: Molecular mechanisms, targeted therapies, and emerging resistance.
28 Jul 2026· Critical reviews in oncology/hematology· PUBMED
Publication
Assessment of phenotypes in a unique group of RET proto-oncogene Y791F variant carriers in the Polish population.
27 Jul 2026· Endokrynologia Polska· PUBMED
Publication
Selpercatinib-Induced Deep Skin Fissures Triggered by Mechanical Friction in a Patient With RET Fusion-Positive Lung Adenocarcinoma.
15 Jul 2026· Respirology case reports· PUBMED
Publication
First-Line Chemoimmunotherapy and Chemotherapy Outcomes in Patients With RET Fusion-Positive Lung Cancer in LIBRETTO-431.
10 Jul 2026· Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer· PUBMED
Publication
Pralsetinib-induced interstitial pneumonitis in a patient with metastatic pulmonary sarcomatoid carcinoma harboring RET fusion: a case report.
10 Jul 2026· AME case reports· PUBMED